(Q33811615)

29 July 2017

1 reference

title

Prognostic factors in multiple myeloma (English)

1 reference

29 July 2017

Rajkumar SV

1

1 reference

29 July 2017

Greipp PR

series ordinal

2

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Hematology / Oncology Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

13

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

1295-314, xi

1 reference

A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

The treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Serum beta2microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

1 reference

7 January 2021

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Serum beta-2-microglobulin binding activity in monoclonal gammopathy: Correlative study and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Cytogenetic study of 30 patients with multiple myeloma: comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Prognostic significance of plasma cell morphology in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

High serum IL-2 levels are predictive of prolonged survival in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Quantification of angiongenesis as an independent predictor of prognosis in invasive bladder carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Risk of disease progression in asymptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

The biological and clinical significance of the KI-67 growth fraction in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Markers of multiple hematopoietic-cell lineages in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

New perspectives in clinical oncology from angiogenesis research

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Tumour angiogenesis and prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Refractory and relapsing multiple myeloma treated by blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

1 reference

7 January 2021

Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Serum beta 2-microglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Electron microscopic analysis of myeloma cells in relation to drug response and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Long-term survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Biology of the Transition of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Acute phase proteins and prognosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Analysis of human myeloma cell population kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Prognostic Relevance of Morphological Classification in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Ras oncogene mutation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Aberrant expression of immunoglobulin light chain isotype in B lymphocytes from patients with monoclonal gammopathies: isotypic discordance and clonal B-cell excess

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Argyrophilic nucleolar organizer region counts and prognosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Cell surface markers in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Immunophenotype and DNA cell content in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Prognostic factors and classification in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Cytogenetic findings in 200 patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Detection of malignant cells in the peripheral blood of patients with multiple myeloma: clinical implications and research applications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

Multiple myeloma: almost all patients are cytogenetically abnormal

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970128-3

7 January 2021

10.1016/S0889-8588(05)70128-3

Identifiers

DOI

1 reference

29 July 2017

1 reference